Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Alan Kivitz"'
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 633-648 (2024)
Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had
Externí odkaz:
https://doaj.org/article/9ce4042ecece4341be994d1a7b7901c4
Autor:
Anisha B. Dua, Kerri Ford, Stefano Fiore, Dimitrios A. Pappas, Jud C. Janak, Taylor Blachley, Carla Roberts-Toler, Kelechi Emeanuru, Joel M. Kremer, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1753-1768 (2023)
Abstract Introduction This observational study evaluated response in patients with rheumatoid arthritis (RA) who switched from an interleukin-6 receptor inhibitor (IL-6Ri) to a Janus kinase inhibitor (JAKi) and vice versa. Methods Adult patients with
Externí odkaz:
https://doaj.org/article/ca669a2fb43c4128bbcdad8bd677d8d4
Autor:
Alan Kivitz, Alvin F. Wells, Juan I. Vargas, Herbert S. B. Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 901-915 (2023)
Abstract Introduction Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label ex
Externí odkaz:
https://doaj.org/article/9b7fbbcc263c40338f0904ba90e40d30
Autor:
Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S. Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K. Kishimoto, Peter G. Traber, Earl Sands, Hyon Choi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 825-847 (2023)
Abstract Introduction SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered wi
Externí odkaz:
https://doaj.org/article/cf6f1cb3ba274f37b044035ffe0ee7d4
Autor:
Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis
Publikováno v:
BMC Rheumatology, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This post hoc analysis eval
Externí odkaz:
https://doaj.org/article/c660845ad6064916b2d9ab800648486d
Autor:
David Gordon, Alan Kivitz, Atul Singhal, David Burt, Madison C. Bangs, Emma E. Huff, Heidi Rath Hope, Joseph B. Monahan
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 2, Pp 63-70 (2023)
Objective The study objective was to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of ATI‐450 with methotrexate in patients with rheumatoid arthritis (RA). Methods A parallel‐assignment, placebo‐controlled, inves
Externí odkaz:
https://doaj.org/article/9707f56a9a9e46caa023363d9f8c3e21
Autor:
Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S. Leung, Lloyd Johnston, Takashi Kei Kishimoto
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-7 (2022)
Anti-drug antibodies (ADA) induced by biologic drugs may hamper the efficacy of treatment, so inhibiting ADA induction is desirable. Here, in two clinical trials, the authors show that ImmTOR, previously reported to reduce drug immunogenicity in anim
Externí odkaz:
https://doaj.org/article/de97b0524c024b9b8277b1e7a9bd7ca8
Autor:
Kurt de Vlam, Alan Kivitz, Andrew J K Ostor, Zailong Wang, Ahmed M Soliman, Ann Eldred, Kim A Papp, Byron Padilla
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objectives Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthe
Externí odkaz:
https://doaj.org/article/838882eaf5b84a6c88601c84524195e0
Autor:
Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheu
Externí odkaz:
https://doaj.org/article/12ab6b3c9513426f81af28505c83a39c
Autor:
Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019)
Abstract Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Methods Subjects completing the final visit in the parent p
Externí odkaz:
https://doaj.org/article/c7545cd42e0d49238435da82651e0291